Errors in Wording and a Percentage

In the Special Communication “Drug Reimbursement Regulation in 6 Peer Countries,” published online in JAMA Internal Medicine on September 28, 2020, there were errors in 2 statements. In first sentence of the fourth paragraph, the phrase “as part of marketing approval” has been removed from the sentence, which now reads: “In Australia, pharmaceutical companies submit clinical and economic evaluations and cost-effectiveness analyses (CEAs) to the Pharmaceutical Benefits Advisory Committee (PBAC), an independent body appointed by the government composed of health care professionals, economists, and consumer represe ntatives.” In the sixth paragraph, the third sentence has been corrected to indicate the correct percentage of price reduction when a second bioequivalent or biosimilar drug enters the market in Australia; it is a 25% reduction, not 16% reduction. In addition, the following sentence was added for clarification: “Manufacturers must disclose ex-factory prices for formulary 2 drugs to the Department of Health, which may decrease the PBS price to meet the ex-factory price.” The article has been corrected online and the corresponding author has offered an explanation in online Comment on the article.
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research